Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Early safety and efficacy of fingolimod treatment in Denmark

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Circulating nociceptin and CGRP in medication-overuse headache

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neurostimulation for the treatment of chronic migraine and cluster headache

    Research output: Contribution to journalReviewResearchpeer-review

  3. Optical coherence tomography in acute optic neuritis: A population-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Married, unmarried, divorced, and widowed and the risk of stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Phenotype and genotype of muscle ryanodine receptor rhabdomyolysis-myalgia syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diagnostic value of oligoclonal bands in children: A Nationwide Population-Based Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Functional neuroimaging of recovery from motor conversion disorder: A case report

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Initiation of fingolimod treatment is associated with a transient decrease of heart rate, and atrioventricular (AV) conduction block may occur.

OBJECTIVE: To evaluate the therapeutic effect and safety of fingolimod treatment in MS patients in Denmark with focus on cardiac and pulmonary side effects at treatment onset.

MATERIALS & METHODS: We analysed data from the first 496 fingolimod-treated Danish patients, observed for at least 3 months. In a subset of 204 patients, we monitored cardiac and pulmonary adverse effects following treatment initiation.

RESULTS: The overall annualized relapse rate (ARR) was 0.37 (95% CI 0.31-0.44); 0.22 (95% CI 0.03-0.81) in de novo-treated patients, 0.29 (95% CI; 0.23-0.37) in patients switching from IFN-beta or GA and 0.46 (9 5% CI 0.34-0.60) after natalizumab. In the subset of 204 patients, 8 (3.9%) required prolonged cardiac monitoring due to bradycardia and/or second-degree AV block type I. All patients recovered spontaneously. Two patients discontinued fingolimod. Eleven (5.4%) patients reported respiratory complaints and two of these patients discontinued treatment.

CONCLUSIONS: Fingolimod appears to be safe and effective in MS patients in a clinical setting. Mild cardiac adverse effects occurred at a similar rate as in clinical trials.

Original languageEnglish
JournalActa Neurologica Scandinavica
Volume135
Issue number1
Pages (from-to)129-133
Number of pages5
ISSN0001-6314
DOIs
Publication statusPublished - Jan 2017

    Research areas

  • Adult, Aged, Cardiotoxicity, Denmark, Female, Fingolimod Hydrochloride, Heart Rate, Humans, Immunosuppressive Agents, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Respiration, Journal Article, Observational Study

ID: 52217844